EU Orphan Drugs: Pricing And Regulatory Barriers More Problematic Than Competitors

Market exclusivity is the key incentive offered under the EU orphan drug framework, but pricing and regulatory problems are the main challenges for rare disease drugmakers, not the pressure from competitors, a life sciences lawyer says.